Posttranslational Modifications in PD-L1 Turnover and Function: From Cradle to Grave
Programmed death-ligand 1 (PD-L1) is one of the most classic immune checkpoint molecules. Cancer cells express PD-L1 to inhibit the activity of effector T cells’ cytotoxicity through programmed death 1 (PD-1) engagement in exposure to inflammatory cytokines. PD-L1 expression levels on cancer cells m...
Guardado en:
Autores principales: | Xinfang Yu, Wei Li, Ken H. Young, Yong Li |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/e72adc11f98441168fc82fd608e91a33 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Expression of Programmed Cell Death-1 (PD-1) and Its Ligand (PD-L1) in Breast Cancers and Its Association with Clinicopathological Parameters: A Study from North India
por: Anoushika Mehan, et al.
Publicado: (2021) -
Sulforaphane enhances the antitumor response of chimeric antigen receptor T cells by regulating PD-1/PD-L1 pathway
por: Chunyi Shen, et al.
Publicado: (2021) -
D-1 / PD-L1 EXPRESSION IN INVASIVE BREAST CARCINOMA / CANCER
por: Sammeen Salim, et al.
Publicado: (2021) -
Multifunctional Immunoliposomes Combining Catalase and PD-L1 Antibodies Overcome Tumor Hypoxia and Enhance Immunotherapeutic Effects Against Melanoma
por: Hei Y, et al.
Publicado: (2020) -
Inhibition of PI3Kδ Differentially Regulates Poly I:C– and Human Metapneumovirus–Induced PD–L1 and PD–L2 Expression in Human Bronchial Epithelial Cells
por: Tomohiro Ogawa, et al.
Publicado: (2021)